Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for
BRCA
Methylation Testing?
JCO Precis Oncol
.
2022 Nov:6:e2200309.
doi: 10.1200/PO.22.00309.
Authors
Tira J Tan
1
2
,
J Lynn Fink
3
4
,
Timothy K Tay
5
,
Binny Jaradi
3
,
Nathan Stone
3
,
Paul Waring
3
,
Kevin M Koo
3
,
Puay Hoon Tan
5
,
Daniel S Tan
1
2
,
Rebecca A Dent
1
2
Affiliations
1
Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
2
Oncology Academic Clinical Program, Duke-NUS Medical School, Singapore, Singapore.
3
XING Genomic Services, Brisbane, Australia.
4
The University of Queensland Diamantina Institute, Brisbane, Australia.
5
Division of Pathology, Singapore General Hospital, Singapore, Singapore.
PMID:
36331241
DOI:
10.1200/PO.22.00309
No abstract available
Publication types
Research Support, Non-U.S. Gov't
MeSH terms
BRCA1 Protein / genetics
Genes, BRCA1
Humans
Methylation
Platinum
Triple Negative Breast Neoplasms* / drug therapy
Substances
Platinum
BRCA1 Protein